VOLITIONRX LTD

VNRX NYSE CIK: 0000093314

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
Mailing Address 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
Phone 1 (512) 774-8930
Fiscal Year End 1231
EIN 911949078

Financial Overview

FY2024

-$7.80M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement February 11, 2026 View on SEC
8-K Current report of material events February 9, 2026 View on SEC
S-3 Shelf registration for future offerings February 9, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC
4 Insider stock transaction report January 23, 2026 View on SEC

Material Events

8-K Financial Distress February 9, 2026
High Impact
  • VolitionRx develops novel blood-based diagnostic tests for serious diseases like cancer.
  • Its Nu.Q® platform technology shows promise.
View Analysis

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.